Elafibranor

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Elafibranor
Elafibranor.svg
Clinical data
SynonymsGFT505, SureCN815512
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H24O4S
Molar mass384.489 g/mol g·mol−1
3D model (JSmol)

Elafibranor (INN,[2] code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).[3][4][5]

Elafibranor is a dual PPARα/δ agonist.[6][7]

See also[edit]

References[edit]

  1. ^ Cariou, B.; Zair, Y.; Staels, B.; Bruckert, E. (2011). "Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients with Combined Dyslipidemia or Impaired Glucose Metabolism". Diabetes Care. 34 (9): 2008–2014. doi:10.2337/dc11-0093. PMC 3161281. PMID 21816979.
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Organization. p. 10. Retrieved 9 November 2016.
  3. ^ "Advanced Compound Status" (Press release). Genfit.
  4. ^ "GFT505 Broadens Its Therapeutic Potential" (PDF) (Press release). Retrieved 31 Mar 2013.
  5. ^ Cariou, Bertrand; Staels, Bart (2014-10-01). "GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes". Expert Opinion on Investigational Drugs. 23 (10): 1441–1448. doi:10.1517/13543784.2014.954034. ISSN 1744-7658. PMID 25164277.
  6. ^ US Patent No. 7655641 "96 dpi image of original patent USPTO 7655641" (PDF). Retrieved 31 Mar 2013.
  7. ^ "GFT-505" (PDF). Drugs of the Future. 37 (8): 555–559. 2012.[permanent dead link]

External links[edit]